186587-70-2

Upstream product

• 100-51-6 benzyl alcohol 
• 35717-98-7 bis(2-propyl)-p-toluenesulfonyloxymethylphosphonate 
• 98-59-9 p-toluenesulfonyl chloride 
• 186593-59-9 (2-Benzyloxy-1-hydroxymethyl-ethoxymethyl)-phosphonic acid diisopropyl ester 
• 99881-46-6 1-(benzyloxy)-3-(trityloxy)-propan-2-ol 

Downstream Products

• 183194-16-3 [1-Benzyloxymethyl-2-(6-cyano-purin-9-yl)-ethoxymethyl]-phosphonic acid diisopropyl ester 
• 183107-05-3 [2-(6-Amino-purin-9-yl)-1-benzyloxymethyl-ethoxymethyl]-phosphonic acid mono-(2-azido-ethyl) ester 
• 183107-01-9 [2-(6-Amino-purin-9-yl)-1-benzyloxymethyl-ethoxymethyl]-phosphonic acid 
• 183194-17-4 [2-(2-Amino-6-cyano-purin-9-yl)-1-benzyloxymethyl-ethoxymethyl]-phosphonic acid diisopropyl ester 

Relevant academic research and scientific papers

Synthesis and antiviral activity of acyclic nucleotide analogues derived from 6-(aminomethyl)purines and purine-6-carboxamidines

The synthesis of a series of 9-(2-phosphonomethoxyalkyl) derivatives of 6-(aminomethyl)purine 11, 2-amino-6-(aminomethyl)purine 12 and purine-6-carboxamidine 14 is reported. The 6-cyanopurines 1 and 2 were selectively alkylated with 2-[bis(isopropyloxy)phosphonylmethoxy]alkyl synthons 3 and 4 at the 9-position. Catalytic hydrogenation of the obtained 9-{2-[bis(isopropyloxy)phosphonylmethoxy]-alkyl}-6-cyanopurines 9 and 10 followed by treatment with bromotrimethylsilane afforded the title compounds 11 and 12. Analogous acyclic nucleotides derived from purine-6-carboxamidines 14 were prepared from the cyanopurines 9a and 10a by treatment with sodium methoxide and ammonium chloride followed by deprotection. Compounds 11 and 12 exhibited moderate activity (MIC50 = 3-50 μg/ml) against herpes simplex virus type 1, varicella-zoster virus and Moloney murine sarcoma virus in vitro.